Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

Johnny Boustany; Maher Abdessater; Charbel El Hachem; Ziad El Khoury; Walid El Khoury; Raghid El Khoury

doi:10.18632/oncotarget.27543

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

Johnny Boustany _, Maher Abdessater, Charbel El Hachem, Ziad El Khoury, Walid El Khoury and Raghid El Khoury

PDF | Full Text | How to cite | Press Release

Oncotarget. 2020; 11:1922-1928. https://doi.org/10.18632/oncotarget.27543

Metrics: PDF 1189 views | Full Text 2128 views | ?

Abstract

Johnny Boustany1^,2, Maher Abdessater1^,2, Charbel El Hachem1^,2, Ziad El Khoury1^,2, Walid El Khoury1^,2 and Raghid El Khoury1^,2

1 Notre Dame des Secours University Hospital Center (CHUNDS), Byblos City, Lebanon

2 Holy Spirit University of Kaslik (USEK), Jounieh, Lebanon

Correspondence to:

Johnny Boustany,

email:

[email protected]

Keywords: clear cell renal carcinoma; sarcomatoid dedifferentiation; metastasectomy; cabozantinib

Received: December 09, 2019 Accepted: March 14, 2020 Published: May 19, 2020

ABSTRACT

Renal cell carcinoma with sarcomatoid dedifferentiation is an entity of RCC that has undergone an anaplastic transformation with both a carcinomatous and a sarcomatous component. The standard treatment in metastatic patients is immunotherapy.

The aim of this article is to describe our case of metastatic recurrent RCC with sarcomatoid dedifferentiation in a 59 year old male patient treated with nephrectomy and multiple metastasectomies followed by Cabozantinib.

Consecutive PET-CT scans showed no evidence of recurrence, three years after the last metastasectomy, and the patient is having currently a normal life.

Sarcomatoid dedifferentiation remains a poor prognosis factor in RCC. Surgery for metastases followed by Cabozantinib may be a therapeutic option in metastatic young patients. However, a prospective randomized trial would be the best option to validate this approach.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27543

Publication Alerts

Post-Publication Promotion

Publication Discount

Case Reports:

Recurrent metastatic clear cell renal carcinoma with sarcomatoid dedifferentiation treated with surgery and Cabozantinib

Abstract